How might adapter-based CAR T cells be used to treat solid tumors effectively?
Adapter-based CAR T cells are a new type of immunotherapy designed to treat solid tumors more effectively. Unlike standard CAR T cells that target only one antigen on cancer cells, adapter-based CAR T cells use small-molecule adapters to redirect the T cells to multiple tumor-associated antigens (TAAs). This flexibility helps overcome a major challenge in solid tumors: antigen escape, where cancer cells stop expressing the targeted antigen and evade treatment. By allowing simultaneous or sequential targeting of different antigens, adapter-based CAR T cells may improve treatment durability and effectiveness against solid tumors.
What the research says
Standard CAR T cell therapy has shown great success in blood cancers, but its effectiveness against solid tumors is limited due to antigen escape and the immunosuppressive tumor microenvironment 69. Adapter-based CAR T cells address antigen escape by using small-molecule adapters that can redirect the T cells to multiple TAAs, making it harder for tumors to evade treatment 69. This platform allows for targeting different antigens without needing to engineer new T cells for each target 69.
However, manufacturing autologous adapter-based CAR T cells (using a patient's own cells) is time-consuming and labor-intensive, and chemotherapy-induced T cell dysfunction can compromise their efficacy 69. To overcome these issues, researchers are developing allogeneic 'off-the-shelf' adapter-based CAR T cells from healthy donors, using gene editing tools like CRISPR/Cas9 to reduce the risk of graft-versus-host disease 69. This approach could make the therapy more accessible and scalable 69.
While adapter-based CAR T cells are a promising strategy, they are still in early development for solid tumors. The sources highlight that this platform is being explored to treat multiple cancer types and overcome antigen escape, but clinical data specific to solid tumors are limited 69. Other challenges for CAR T cells in solid tumors, such as the hostile tumor microenvironment, also need to be addressed 28.
What to ask your doctor
- Are there any clinical trials for adapter-based CAR T cells available for my type of solid tumor?
- How does the adapter-based approach differ from standard CAR T therapy in terms of side effects and effectiveness?
- What tumor-associated antigens are being targeted in current adapter-based CAR T studies?
- Is there any evidence that adapter-based CAR T cells can prevent antigen escape in my cancer?
- Would I be a candidate for an allogeneic 'off-the-shelf' CAR T product if one is available?
This question is drawn from common patient questions about this topic and answered using cited medical research. We do not provide individualized advice.